Vadim Uzberg is a Partner at Negev Capital, a venture capital firm specializing in psychedelic medicine. He has an extensive background in private equity, including a long tenure as a Partner at Baring Vostok Capital Partners. He leverages deep expertise in M&A, deal structuring, and monitoring portfolio companies, and holds an economics degree from Voronezh State University.
His fund, Negev Capital, recently marked a major success with the acquisition of a clinical program from their portfolio company, Gilgamesh Pharmaceuticals, by AbbVie for $1. 2 billion.
Vadim Uzberg
Partner at Negev Capital
Limassol, Cyprus
Overview
Topics They Care About
Psychedelic Medicine
As a Partner at Negev Capital, his firm's primary investment focus is on companies developing psychedelic-based therapies for various health conditions.
Private Equity
Possesses a long and distinguished career in private equity, formerly as a Partner at Baring Vostok and currently with Negev Capital.
Biotech M&A
A recent successful exit involved AbbVie's acquisition of a clinical program from portfolio company Gilgamesh Pharmaceuticals, highlighting his activity in biotech mergers and acquisitions.
Media Appearances
Vadim has no verified media appearances
Work History
12-2021
Partner at Negev Capital
3-2005 - 7-2020
Partner at Baring Vostok Capital Partners
1999 - 2005
Chief Financial Officer at Eagle Venture Partners
Education
2008 - 2009
Education details unavailable from Harvard Business School
1994 - 2002
Economics from Voronezh State University
More Information
Social Presence :
Prographics :
Exp : 25
Location : Limassol, Cyprus
Job Level : N/A
Designation : Partner at Negev Capital
